抄録
Induced pluripotent stem cells (iPSCs) have become a prevalent topic after their discovery, advertised as an ethical alternative to embryonic stem cells (ESCs). Due to their ability to differentiate into several kinds of cells, including cardiomyocytes, researchers quickly realized the potential for differentiated cardiomyocytes to be used in the treatment of heart failure, a research area with few alternatives. This paper discusses the differentiation process for human iPSC-derived cardiomyocytes and the possible applications of said cells while answering some questions regarding ethical issues.
本文言語 | 英語 |
---|---|
論文番号 | 237 |
ジャーナル | Bioengineering |
巻 | 10 |
号 | 2 |
DOI | |
出版ステータス | 出版済み - 2023/02 |
ASJC Scopus 主題領域
- バイオエンジニアリング